All News

Avidin has developed a novel blood based diagnostic test that measures acquired T-cell immunity against the SARS-CoV2 coronavirus, following infection or immunization. Avidin is the first private company to offer such a test in Hungary.

Avidin’s Budapest site (Berlini u 47-49) was accredited as M3 authorization level of microbiological diagnostics laboratory.

Avidin’s enthusiastic team has participated in Hungarian Shoe Box Campaign, a child-assisting program, under which Christmas presents are donated to children in need.

The aim of the project was the acquisition of the Advia Centaur® XPT immunochemical automate system manufactured by Siemens, followed by the adaptation of the test assays provided by the instrument.

New patent application of anti-cancer drug candidate.

Avidin can simultaneously check for Covid-19 and Influenza infection from the same specimen by using its multi-diagnostic PCR solution with high specificity and sensitivity.

Avidin, led by Dr. Liliana Fehér, has developed its own one-step RT-PCR kit, the Cov2QuantTM SARS-Cov-2 Quantification kit (cat: CQ-100), designed to detect the novel corona virus, SARS-Cov-2, quantitatively by using reverse trascription reaction and quantitative real-time polymerase chain reaction.

Avidin has expanded the company’s portfolio with a specialized clinical molecular diagnostics department focused on the detection and monitoring of infectious diseases.

Avidin set up viral diagnostics lab and developed own reagents and method to combat Covid-19 reported by HVG 05/28/2020 Avidin, reported by HVG (Weekly World